Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug;22(4):e13343.
doi: 10.1111/tid.13343. Epub 2020 Jun 23.

A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients

Mari Eriksson  1 , Helena Käyhty  2 , Heikki Saha  3 , Mika Lahdenkari  2 , Petri Koskinen  4 , Heikki Mäkisalo  5 , Veli-Jukka Anttila  1
Affiliations
Clinical Trial

A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients

Mari Eriksson et al. Transpl Infect Dis. 2020 Aug.

Abstract

Background: The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known.

Methods: The potential kidney transplant recipients in dialysis were randomized into two arms: to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before transplantation and a second dose of PCV13 six months after the transplantation. Serotype-specific antibody concentrations and opsonophagocytic activity (OPA) were measured before and after the first vaccination (visits V1,V2) and six and seven months after the transplantation, for example, before and after the second PCV13 (visits V3,V4).

Results: Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study. After the first vaccination, the geometric mean concentrations (GMCs) in the PCV13 arm were significantly higher for 9/13 serotypes and the OPA geometric mean titers (GMTs) were significantly higher for 4/13 serotypes. At V3, the antibody levels had declined but OPA remained significantly higher for 7/13 (PCV13) vs 4/13 (PPV23) serotypes. At V4, the GMCs for 9/13 serotypes and the GMTs for 12/13 serotypes were significantly higher in the PCV13 arm. The GMCs but not GMTs were lower than at V2. There was no difference in adverse effects. No vaccine-related allograft rejection was detected.

Conclusions: The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe.

Keywords: dialysis; kidney transplant recipient; pneumococcal disease; pneumococcal vaccination.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D. Invasive pneumococcal disease in solid organ transplant recipients: 10-year prospective population surveillance. Am J Transplant. 2007;7:1209-1214.
    1. Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti P. Invasive pneumococcal disease among persons with and without underlying medical conditions. Implications for prevention strategies. BMC Infect Dis. 2008;8:96.
    1. Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practise. Clin Transplant. 2019;33(9):e13563.
    1. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318.
    1. Disease K. Improving Global outcomes (KDIGO) Transplant Work Group. KDIGO clinical practise guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-S157.

Publication types

Substances

Grants and funding